Details for Patent: 9,669,019
✉ Email this page to a colleague
Which drugs does patent 9,669,019 protect, and when does it expire?
Patent 9,669,019 protects KYNMOBI and is included in one NDA.
This patent has forty-seven patent family members in nineteen countries.
Summary for Patent: 9,669,019
| Title: | Sublingual apomorphine |
| Abstract: | Disclosed are sublingual formulations of apomorphine in unit dosage form formulated for sublingual administration, where the unit dosage form is a mucoadhesive film containing a pH neutralizing agent and apomorphine particles containing an acid addition salt of apomorphine, and where the mucoadhesive film is formed by the steps of: (i) combining a film-forming mucoadhesive polymer, apomorphine particles comprising an acid addition salt of apomorphine, and a solvent to form a mixture; and (ii) pouring the mixture onto a surface and evaporating some of the solvent to form a first film comprising the apomorphine particles, where the steps further include contacting or impregnating the first film or mixture with a pH neutralizing agent to produce the mucoadhesive film containing the apomorphine particles and the pH neutralizing agent. |
| Inventor(s): | Giovinazzo; Anthony John (Caledon, CA), Hedden; David Bruce (Ann Arbor, MI), De Somer; Marc L. (Winchester, MA), Bryson; Nathan John (Toronto, CA) |
| Assignee: | Sunovion Pharmaceuticals Inc. (Marlborough, MA) |
| Application Number: | 14/963,910 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,669,019
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Sign Up | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Sign Up | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Sign Up | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Sign Up | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-005 | May 21, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,669,019
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010259971 | ⤷ Sign Up | |||
| Australia | 2017200329 | ⤷ Sign Up | |||
| Australia | 2019200308 | ⤷ Sign Up | |||
| Australia | 2021201259 | ⤷ Sign Up | |||
| Brazil | 112012000204 | ⤷ Sign Up | |||
| Canada | 2765291 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
